Aurinia Refocusing After Failed Effort To Find A Buyer
By Yeji Jesse Lee · February 15, 2024, 6:00 PM EST
Kidney-focused biotech Aurinia Pharmaceuticals is hitting pause on drug development, cutting jobs and initiating a $150 million stock buyback program, the company disclosed in its year-end financial report Thursday....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login